Treatment of Bipolar I Rapid Cycling Patients During Dysphoric Mania with Olanzapine
- 1 October 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 22 (5) , 450-454
- https://doi.org/10.1097/00004714-200210000-00002
Abstract
The simultaneous presentation of manic and depressive symptoms in the same patient is fairly common. The terms dysphoric, mixed, and depressive mania have been used as equivalents to mixed states. Pharmacotherapy is less effective in this group of patients. The aim of this study is to determine the effectiveness and safety of olanzapine as an add-on therapy in patients with bipolar disorder with a rapid cycling course during a dysphoric mania episode. Thirteen patients treated with mood stabilizers for at least 1 year and diagnosed with a mixed episode were included in an open trial. All had at least 4 episodes in the last year. Patients with organic diseases, including altered thyroid function, were excluded from the research. Patients were evaluated at inclusion and at day 28. Response was defined as a decrease of 50% in the Young Mania Rating Scale and the Hamilton Rating Scale for Depression concomitant with a Clinical Global Impression improvement of 1 or 2. All patients completed the study. The doses of olanzapine were 16.15 ± 5.82 mg/day. There was a reduction in the manic and depressive symptoms in all patients. Ten of the 13 patients were considered to have responded to the treatment according to the response definition. Adverse effects included somnolence (23.08%) and weight gain (0.81 ± 1.96 kg in women, 2.20 ± 2.28 kg in men). Our results suggest that olanzapine combined with mood stabilizers is safe and effective in the treatment of the manic and the depressive symptoms of dysphoric mania with a rapid cycling course.Keywords
This publication has 25 references indexed in Scilit:
- Clozapine- and Olanzapine-induced Fos Expression in the Rat Medial Prefrontal Cortex is Mediated by β-AdrenoceptorsNeuropsychopharmacology, 2000
- A Randomized, Placebo-Controlled 12-Month Trial of Divalproex and Lithium in Treatment of Outpatients With Bipolar I DisorderArchives of General Psychiatry, 2000
- Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D 2 and serotonin 5-HT 2A receptors in the rat brainJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2000
- Clozapine in Rapid Cycling Bipolar DisorderJournal of Clinical Psychopharmacology, 1996
- Lithium enhances 5-HT2Areceptor-mediated c-fos expression in rat cerebral cortexNeuroReport, 1993
- Possible Bupropion Precipitation of Mania and a Mixed Affective StateJournal of Clinical Psychopharmacology, 1991
- Effects of chronic lithium treatment on serotonin binding sites in rat brainJournal of Psychiatric Research, 1990
- Dopamine in manic depressive illness: A pharmacological synthesisJournal of Affective Disorders, 1985
- Flupenthixol decanoate in recurrent manic‐depressive illnessActa Psychiatrica Scandinavica, 1981
- Long-Term Antidepressant Treatment Decreases Spiroperidol-Labeled Serotonin Receptor BindingScience, 1980